Brendon Neuen's Publications

About Brendon Neuen's Publications

Program Lead, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM

    Nephrology Dialysis Transplantation Date published:

  • P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL

    Nephrology Dialysis Transplantation Date published:

  • P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL

    Nephrology Dialysis Transplantation Date published:

  • Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study

    Diabetes Care Date published:

  • 1054-05 EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

    Date published:

  • EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION

    Journal of the American College of Cardiology Date published:

  • EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

    Journal of the American College of Cardiology Date published:

  • EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL

    Journal of the American College of Cardiology Date published:

  • Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

    Journal of the American Heart Association Date published:

  • Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

    Nephrology Dialysis Transplantation Date published:

  • Pilot Trials in Nephrology: Establishing a BASE for Large-Scale Randomized Trials

    Journal of the American Society of Nephrology Date published:

  • SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

    The Lancet Diabetes & Endocrinology Date published:

  • A longitudinal faculty development program: supporting a culture of teaching

    BMC Medical Education Date published:

  • Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey

    BMJ Date published:

  • Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering

    Canadian Medical Association Journal Date published: